These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
506 related articles for article (PubMed ID: 25316657)
1. FAK signaling in human cancer as a target for therapeutics. Lee BY; Timpson P; Horvath LG; Daly RJ Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657 [TBL] [Abstract][Full Text] [Related]
2. Focal adhesion kinase: a potential target in cancer therapy. van Nimwegen MJ; van de Water B Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283 [TBL] [Abstract][Full Text] [Related]
5. Signal transduction by focal adhesion kinase in cancer. Zhao J; Guan JL Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797 [TBL] [Abstract][Full Text] [Related]
6. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065 [TBL] [Abstract][Full Text] [Related]
7. FAK expression regulation and therapeutic potential. Li S; Hua ZC Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942 [TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase as a cancer therapy target. Golubovskaya VM Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510 [TBL] [Abstract][Full Text] [Related]
9. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525 [TBL] [Abstract][Full Text] [Related]
10. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. Yoon H; Dehart JP; Murphy JM; Lim ST J Histochem Cytochem; 2015 Feb; 63(2):114-28. PubMed ID: 25380750 [TBL] [Abstract][Full Text] [Related]
11. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579 [TBL] [Abstract][Full Text] [Related]
12. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Schultze A; Fiedler W Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362 [TBL] [Abstract][Full Text] [Related]
15. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). Lu Y; Sun H J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606 [TBL] [Abstract][Full Text] [Related]
17. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Yang M; Xiang H; Luo G Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282 [TBL] [Abstract][Full Text] [Related]
18. Emerging roles of focal adhesion kinase in cancer. Tai YL; Chen LC; Shen TL Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719 [TBL] [Abstract][Full Text] [Related]
19. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Crompton BD; Carlton AL; Thorner AR; Christie AL; Du J; Calicchio ML; Rivera MN; Fleming MD; Kohl NE; Kung AL; Stegmaier K Cancer Res; 2013 May; 73(9):2873-83. PubMed ID: 23536552 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]